Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.75 |
| ▸ | NPC1 | O15118 | 4/20 | 0.75 |
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.71 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.71 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.69 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25138816 | 0.95 | RAB9A (0.91) | RAB9ASMN1; SMN2NPC1HTTMAPT | |
| SCHEMBL677703 | 0.93 | RAB9A (0.86) | RAB9ASMN1; SMN2NPC1HTTMAPT | |
| SCHEMBL6242208 | 0.92 | RAB9A (0.84) | RAB9ASMN1; SMN2NPC1HTTMAPT | |
| SCHEMBL23070479 | 0.89 | RAB9A (0.80) | RAB9ASMN1; SMN2NPC1HTTMAPT | |
| SCHEMBL25262559 | 0.88 | RAB9A (0.79) | RAB9ASMN1; SMN2NPC1HTTMAPT | |
| SCHEMBL1815384 | 0.88 | RAB9A (0.80) | RAB9ASMN1; SMN2NPC1HTTMAPT | |
| SCHEMBL1815533 | 0.88 | RAB9A (0.78) | RAB9ASMN1; SMN2NPC1HTTMAPT | |
| SCHEMBL11710023 | 0.86 | RAB9A (0.76) | RAB9ASMN1; SMN2NPC1MAPTTP53 | |
| SCHEMBL16681258 | 0.86 | RAB9A (0.75) | RAB9ASMN1; SMN2NPC1HTTMAPT | |
| SCHEMBL14096335 | 0.85 | RAB9A (0.77) | RAB9ASMN1; SMN2NPC1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104739820-A | Small molecule inhibitor and application thereof to inhibiting ornithine decarboxylase (ODC) | UNIV CHINA THREE GORGES CTGU | 2015-07-01 | — | — | CN | disclosed |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| EP-2292587-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING THE TRANSCRIPTION FACTOR INDUCIBLE BY HYPOXIA, MODULATORS OF PATHOLOGICAL PROCESSES OF ANGIOGENESIS, ONCOGENESIS, INFLAMMATION, APOPTOSIS, AND CELLULAR THERAPY | Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (ES) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292587-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING THE TRANSCRIPTION FACTOR INDUCIBLE BY HYPOXIA, MODULATORS OF PATHOLOGICAL PROCESSES OF ANGIOGENESIS, ONCOGENESIS, INFLAMMATION, APOPTOSIS, AND CELLULAR THERAPY | Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (ES) | 2011-03-09 | — | — | EP | disclosed |
| EP-2166841-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | Mission Pharmacal Company (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | VIP, PDE3B, ADCY5 | RAB9A 1654/4885SMN1; SMN2 4854/4885NPC1 2304/4885 |
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | RAB9A 3175/4885SMN1; SMN2 1886/4885NPC1 1139/4885 |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | RAB9A 1654/4885SMN1; SMN2 4854/4885NPC1 2304/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | RAB9A 3175/4885SMN1; SMN2 1886/4885NPC1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.